Beata Krasińska1, Lech Paluszkiewicz2, Ewa Miciak-Lawicka3, Maciej Krasiński4, Piotr Rzymski5, Andrzej Tykarski3, Zbigniew Krasiński6. 1. Department of Hypertension, Angiology and Internal Diseases, Poznan University of Medical Sciences, Poznan, Poland. beata.bkrasinska@gmail.com. 2. Department of Thoracic And Cardiovascular Surgery/Perioperative diagnostics Bad Oeynhausen, Heart and Diabetes Center NRW, Ruhr-University of Bochum, Germany. 3. Department of Hypertension, Angiology and Internal Diseases, Poznan University of Medical Sciences, Poznan, Poland. 4. Student, Imperial College London School of Medicine, United Kingdom. 5. Department of Environmental Medicine, Poznan University of Medical Sciences, Poznan, Poland. 6. Department of General and Vascular Surgery, Poznan University of Medical Sciences, Poznan, Poland.
Abstract
BACKGROUND:Acetylsalicylic acid (ASA) is one of the basic drugs used in the secondary prevention of coronary artery disease (CAD), and in most cases it is taken in the morning in one daily dose. It is suggested that the morning peak of platelet aggregation is responsible for the occurrence of myocardial infarctions and strokes. Hence, the aim of the study was to observe the effect of ASA (morning vs. evening) dosing on the anti-aggregative effect of platelets in patients with CAD and arterial hypertension (AH). METHODS: The study involved 175 patients with CAD and AH. Patients were randomly assigned to one of two study groups, taking ASA in the morning or in the evening. The patients had two visits, one baseline and another after 3 months from changing the time of ASA dosage. The platelet aggregation was determined using the VerifyNow analyzer. RESULTS: In the ASA evening group, a significant reduction in platelet aggregation was obtained. In the ASA morning group, a significant difference in response to ASA was observed, depending on sex. In men, the reactivity of platelets decreased, but in women it increased. CONCLUSIONS: In the group of patients with CAD and AH, bedtime ASA dosing is associated with a significant reduction in platelet aggregation. The response to ASA may differ between sexes. The benefit gained by changing the drug administration from the morning to the evening is greater in women.
RCT Entities:
BACKGROUND:Acetylsalicylic acid (ASA) is one of the basic drugs used in the secondary prevention of coronary artery disease (CAD), and in most cases it is taken in the morning in one daily dose. It is suggested that the morning peak of platelet aggregation is responsible for the occurrence of myocardial infarctions and strokes. Hence, the aim of the study was to observe the effect of ASA (morning vs. evening) dosing on the anti-aggregative effect of platelets in patients with CAD and arterial hypertension (AH). METHODS: The study involved 175 patients with CAD and AH. Patients were randomly assigned to one of two study groups, taking ASA in the morning or in the evening. The patients had two visits, one baseline and another after 3 months from changing the time of ASA dosage. The platelet aggregation was determined using the VerifyNow analyzer. RESULTS: In the ASA evening group, a significant reduction in platelet aggregation was obtained. In the ASA morning group, a significant difference in response to ASA was observed, depending on sex. In men, the reactivity of platelets decreased, but in women it increased. CONCLUSIONS: In the group of patients with CAD and AH, bedtime ASA dosing is associated with a significant reduction in platelet aggregation. The response to ASA may differ between sexes. The benefit gained by changing the drug administration from the morning to the evening is greater in women.
Authors: E Franco; I J Núñez-Gil; D Vivas; B Ruiz Mateos; B Ibañez; N Gonzalo; C Macaya; A Fernández Ortiz Journal: Eur J Intern Med Date: 2011-08-23 Impact factor: 4.487
Authors: Aida Suárez-Barrientos; Pedro López-Romero; David Vivas; Francisco Castro-Ferreira; Ivan Núñez-Gil; Eduardo Franco; Borja Ruiz-Mateos; Juan Carlos García-Rubira; Antonio Fernández-Ortiz; Carlos Macaya; Borja Ibanez Journal: Heart Date: 2011-04-27 Impact factor: 5.994
Authors: Joep Perk; Guy De Backer; Helmut Gohlke; Ian Graham; Zeljko Reiner; W M Monique Verschuren; Christian Albus; Pascale Benlian; Gudrun Boysen; Renata Cifkova; Christi Deaton; Shah Ebrahim; Miles Fisher; Giuseppe Germanò; Richard Hobbs; Arno Hoes; Sehnaz Karadeniz; Alessandro Mezzani; Eva Prescott; Lars Ryden; Martin Scherer; Mikko Syvanne; Wilma J M Scholte Op Reimer; Christiaan Vrints; David Wood; Jose Luis Zamorano; Faiez Zannad Journal: G Ital Cardiol (Rome) Date: 2013-05
Authors: T N Bonten; A Saris; M J van Oostrom; J D Snoep; F R Rosendaal; J Zwaginga; J Eikenboom; P F van der Meer; J G van der Bom Journal: Thromb Haemost Date: 2014-09-11 Impact factor: 5.249
Authors: N J Breet; M A Sluman; M A J P J van Berkel; J W van Werkum; H J Bouman; A M Harmsze; J C Kelder; F Zijlstra; C M Hackeng; J M Ten Berg Journal: Neth Heart J Date: 2011-11 Impact factor: 2.380